CBD-DACannabidiol diacetate
Semi-synthetic acetic diester of CBD, a research analogue found in grey-market products.
C₂₅H₃₄O₄
CAS 40525-15-3
- Family
- Semi-synthetic cannabinoidEster or prodrug
- Molar mass
- 398.54 g/mol
Updated on
In plain terms
Cannabidiol diacetate is chemically modified CBD: its two "OH" groups are turned into acetates. It was tested in animals as early as 1981 and was found in 2022 in products sold without oversight in the United States. Its effects in humans have never been studied.
Receptors and activity
Measured effects
Not characterised. No placebo-controlled human trial has measured the effects of CBD-DA, so no level is shown.
Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method
Pharmacology
Cannabidiol diacetate (CBD-DA) is the acetic diester of cannabidiol, in which both phenol functions of the resorcinol ring are acetylated. Consroe et al. (1981) compared it with CBD in rats: given intravenously, it was as effective as CBD against audiogenic seizures, with lower rotarod neurotoxicity, and inactive in rabbits susceptible to THC-induced seizures. Morales et al. (2017) suggest these diacetates might behave as CBD prodrugs, a hypothesis no measurement has verified. Holt et al. (2022) reported the first identification of this compound in commercial products, plant material and gummies that also contained Δ8-THC and THC acetates, in a case involving hallucinations. No receptor binding, pharmacokinetic or human safety data have been published.
Key sources.
- Consroe P, Martin A, Singh V. Antiepileptic potential of cannabidiol analogs. J Clin Pharmacol 1981;21(S1):428S-436S (new tab)PMID 7298873
- Morales P, Reggio PH, Jagerovic N. An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol. Front Pharmacol 2017;8:422 (new tab)PMID 28701957
- Holt AK, Poklis JL, Peace MR. ∆8-THC, THC-O acetates and CBD-di-O acetate: emerging synthetic cannabinoids found in commercially sold plant material and gummy edibles. J Anal Toxicol 2022;46:940-948 (new tab)PMID 35674405
- PubChem CID 15139512, Cannabidiol diacetate (CAS 40525-15-3) (new tab)
- ANSM, decision of 22 May 2024 amending the list of substances classified as narcotics (generic benzo[c]chromene class), supplemented by the decision of 3 June 2024 (new tab)
- ANSM, consolidated list of substances classified as narcotics, updated 26/06/2026 (new tab)
History
- Source
- Absent from cannabis: it is the acetic diester of cannabidiol, both of whose phenol functions are acetylated. It served as an analogue in pharmacological research (Consroe et al. 1981) and has been identified in grey-market products in the United States (Holt et al. 2022).
Route of preparation
Chemical process
No plant pathway. It is a semi-synthetic acetic diester of cannabidiol, described here by chemical class only.
Legal framework
- European Union
Not listed in the UN conventions, and no European Union measure of its own was found. No authorisation under Regulation (EU) 2015/2283 on novel foods was found for this compound. Checked 20/10/2026.
- France
Not named in the French narcotics list. Cannabidiol is not a narcotic, and its diacetate is not a tetrahydrocannabinol; lacking a pyran ring, it does not have the benzo[c]chromene nucleus targeted by the 2024 generic class (ANSM decisions of 22 May and 3 June 2024). Those same decisions did, however, list by name two other semi-synthetic CBD derivatives, H2-CBD and H4-CBD. Checked 20/10/2026.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Semi-synthetic cannabinoid › Ester or prodrug
- Chemistry
C5 side chain · neutral form
- Verification
Every fact on this entry was checked against its primary sources on 20 October 2026.
- Wikipedia (English)
Cannabidiol diacetate (new tab)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Consroe P, Martin A, Singh V. Antiepileptic potential of cannabidiol analogs. J Clin Pharmacol 1981;21(S1):428S-436S (new tab)PMID 7298873
- Morales P, Reggio PH, Jagerovic N. An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol. Front Pharmacol 2017;8:422 (new tab)PMID 28701957
- Holt AK, Poklis JL, Peace MR. ∆8-THC, THC-O acetates and CBD-di-O acetate: emerging synthetic cannabinoids found in commercially sold plant material and gummy edibles. J Anal Toxicol 2022;46:940-948 (new tab)PMID 35674405
- PubChem CID 15139512, Cannabidiol diacetate (CAS 40525-15-3) (new tab)
- ANSM, decision of 22 May 2024 amending the list of substances classified as narcotics (generic benzo[c]chromene class), supplemented by the decision of 3 June 2024 (new tab)
- ANSM, consolidated list of substances classified as narcotics, updated 26/06/2026 (new tab)
Identifiers
Names
- Common name
- Cannabidiol diacetate
- IUPAC name
- [3-acetyloxy-2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylphenyl] acetate
- Other names
- CBD-DA
Identifiers
- Formula
- C₂₅H₃₄O₄
- CAS
- 40525-15-3
- PubChem CID
- 15139512(new tab)
- InChIKey
- UCYSPYOYJNVCAI-FCHUYYIVSA-N
- SMILES
- CCCCCC1=
CC(= C(C(= C1) OC(= O) C) [C@@H] 2C= C(CC[C@H] 2C(= C) C) C) OC(= O) C
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.